January 27, 2017
RegMedNet interview with Masayo Takahashi highlights importance of iPSC therapies
RegMedNet today published an exclusive interview with Masayo Takahashi, Project Leader for Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (Kobe, Japan), as part of their spotlight on iPSC production. Dr Takahashi was the lead researcher in the first human trial for iPSCs, which was cancelled in 2015 due in part to safety concerns: in the interview she discusses the difficulties in producing stable iPSCs and the potential of iPSC therapy.
“I think [the future for iPSC therapy] is very promising,” explained Dr Takahashi. “Without a doubt, regenerative medicine will become a big field in the future.”
“iPSCs are a rapidly developing field and Dr Takahashi’s work demonstrates that there are clear applications for this research,” commented Freya Leask, RegMedNet Editor and Community Manager. “However, it also illustrates that further study is required in order to maximize the therapeutic potential of iPSCs and ensure the safety and efficacy of regenerative medicines in general.”
The RegMedNed spotlight on iPSCs is a 2-month feature that will focus on the challenges in their production that have hampered attempts to bring related therapies to clinic. The spotlight features exclusive interviews with leaders in the field, plus free peer-reviewed articles from Future Science Group titles Future Oncology, Epigenomics and Regenerative Medicine. It also includes a survey, the results of which will be discussed by an expert panel at the end of the spotlight, that will be free to watch and available on-demand afterwards.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.